In 1935, Cipla was founded by Dr.Khwaja Abdul Hamied as a small Indian enterprise that was committed to nation’s quest for self-sufficiency. During the Second World War Cipla proved itself by meeting the challenge of alarming shortage of essential medicines. Cipla pioneered the bulk drug manufacturing market by the 1960s.
Cipla has committed production plants for Oncology products, Hormones, Inhalers, Carbapenems, and cephlosporins, among other products. Its API manufacturing plants have the capability of complex multi-stage syntheses and can manufacture over 120 APIs from high potency actives in grams to those made in several tonnes.
Cipla has a wide range of products and dosages forms, everything from nasal sprays, metered-dose inhalers, medical devices, trans-dermal spray patches, thermolabile foams, pre-filled syringes, and lyophilized injections.
Cipla has 7000 employees, who are known for their continuous quest for quality. For them quality is obsession.
Cipla had opened the door of hope to several AIDS patients by becoming the first company in the world to offer the Triple-drug AIDS Cocktail at a very low price. According to an estimate, one out of three HIV-AIDS patients in Africa takes Cipla drug for the treatment.
In partnership with the medical fraternity, Cipla has spread awareness and empowered asthma patients to lead a normal life. It has the widest range of asthma medication and better delivery systems. Cipla is also dedicated to clinical and allied research in the field of Chronic Respiratory Diseases.
Recently, the company has entered into agreement with a global non-profit organization for developing and manufacturing Drugs for Neglected diseases Initiative (DNDi) for a new anti-malarial combination drug.
Mumbai 400 008
Quarterly Reports of Cipla
|Dec 2006 (3 rd quarter)||Sept 2006(2nd quarter)||Dec 2005 (3 rd quarter)|
|% Change (Over Sep 2006)||% Change (Over Dec 2005)|
Annual Results of Cipla
|(12 Months)||(12 Months)||% Changes|